High potency ADCs - from discovery to the clinic

The KTN will be holding this event, in partnership with MedImmune, on Monday 11 December 2017 in Cambridge. The aim of the meeting is to bring together the Antibody Drug Conjugate discovery, development and manufacturing community in human health in the UK. Come and join us to:

• learn about the latest innovative technologies in target identification, process development and manufacturing of all component parts of ADCs

• catch up on novel toxins and linkers being developed

• share in the success of ADCs already in clinical development

Hear about

o UK capabilities and future opportunities for this sector, identified in the MMIP Technology and Innovation workstream

o funding opportunities to support innovative companies through Innovate UK, and mechanisms such as the Industrial Strategy Challenge Fund

We are expecting about 90 delegates on the day from the wider sector. Thanks to the generosity of our hosts, and supporters including Glythera and ADC Biotechnology, the KTN is able to deliver this meeting as a free event for the community. This one day event aligns with the KTN’s activities in medicines bioprocessing and manufacturing, as well as the Medicines Manufacturing Industry Partnership (MMIP).

Call for posters - there will be a chance for researchers to present posters. Please note your interest on registration and use the free text box to indicate title and short descriptor.

Please note, places for this event are limited and if the meeting is oversubscribed, places will be prioritised for those who are technical practitioners in the sector.